Fulcrum Therapeutics, Inc. — FY 2023 Form 10-K
Business context and reporting period. Fulcrum is a clinical-stage biopharmaceutical company developing small molecules for genetically defined rare diseases. This annual report covers the fiscal year ended December 31, 2023; it does not provide separate fourth-quarter financial results. Its two clinical-stage candidates are losmapimod for facioscapulohumeral muscular dystrophy (FSHD) and pociredir for sickle cell disease (SCD). The company reported no product sales.
Key financial metrics
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Collaboration revenue | $2.8 million | $6.3 million |
| Research and development expense | $71.8 million | $76.8 million |
| General and administrative expense | $41.7 million | $41.7 million |
| Operating loss | $110.7 million | $112.6 million |
| Other income, net | $13.3 million | $2.7 million |
| Net loss | $97.3 million | $109.9 million |
| Net loss per share, basic and diluted | $1.59 | $2.44 |
| Net cash used in operating activities | $91.0 million | $97.1 million |
Liquidity and capital. At December 31, 2023, cash and cash equivalents were $25.6 million and marketable securities were $210.7 million, totaling approximately $236.2 million. Current assets were $242.2 million and current liabilities were $13.7 million. Total liabilities were $22.5 million, including $10.8 million of operating lease liabilities; the filing reports no conventional debt balance. The company raised $117.3 million net from a January 2023 common-stock offering. Management estimates existing cash, cash equivalents and marketable securities will fund operating expenses and capital expenditures into 2026, subject to assumptions and potential changes in its operating plan.
Margins. Product revenue has not begun, so commercial gross margins are not applicable. The filing reports no clear product-level margin measure.
Material changes versus the prior comparable period
- Net loss narrowed by $12.5 million, principally because other income rose $10.6 million as investment returns and average cash and securities balances increased. Operating loss improved by $1.9 million.
- R&D expense declined $5.0 million. Lower pociredir spending during the February–August 2023 clinical hold and the prior-year $5.0 million GSK milestone contributed; higher REACH trial costs partly offset the decline.
- Collaboration revenue fell $3.5 million, including the absence of Acceleron revenue after its agreement terminated in October 2022 and lower MyoKardia revenue.
- Operating cash use decreased by $6.1 million. Investing activities used $36.7 million in 2023, primarily reflecting net purchases of marketable securities, compared with $12.4 million provided in 2022.
- Common shares outstanding increased from 52.1 million at year-end 2022 to 61.9 million at year-end 2023, primarily reflecting the January 2023 public offering.
Outlook, management commentary, risks and unusual items
- Losmapimod: The Phase 3 REACH trial enrolled 260 adults and completed enrollment in September 2023. The company expects topline results in the fourth quarter of 2024. REACH’s primary endpoint is change from baseline in reachable workspace (RWS). The earlier Phase 2b ReDUX4 trial missed its primary biomarker endpoint; reported benefits on secondary and exploratory measures were nominal analyses, so pivotal efficacy remains uncertain.
- Pociredir: The FDA imposed a full clinical hold in February 2023 after nonclinical toxicology studies identified hematological malignancies; the hold was lifted in August 2023. The company is re-initiating Phase 1b at 12 mg once daily, with an expected cohort of about 10 patients, followed by about 10 patients at 20 mg. The protocol was revised to target patients with higher disease severity. Early, interrupted-cohort data showed HbF increases, but the filing cautions that safety concerns, including malignancy risk, remain unresolved.
- Strategy and spending: Fulcrum is prioritizing its two clinical-stage candidates and selected preclinical muscle and hematology programs, while winding down certain exploratory discovery activities. It expects substantial operating losses and negative operating cash flows to continue and will need additional funding. It terminated its prior $50 million ATM agreement and stated it anticipated establishing a new ATM program of up to $100 million after filing; any sales depend on an effective registration statement and market conditions.
- Partnerships and obligations: MyoKardia collaboration revenue was $2.8 million in 2023; potential future milestones and royalties depend on development and commercial success. The July 2023 CAMP4 license adds a Diamond Blackfan Anemia program, with an undisclosed upfront payment and potential milestone and royalty obligations.
- Litigation: A securities class action related to statements and disclosures surrounding the pociredir clinical hold is pending; defendants’ motion to dismiss was pending at year-end. The company says it intends to defend the case. No clear loss estimate is provided in the filing.
- Other risks: The business depends on clinical-trial outcomes, external manufacturers and CROs, additional capital, intellectual-property protection, and future regulatory and reimbursement decisions. The company also noted recent executive transitions and potential operational distraction.
Investor verification priorities
- Track REACH execution, the RWS endpoint, and the expected Q4 2024 topline timing; assess how the Phase 2 primary-endpoint miss affects interpretation of pivotal results.
- Review pociredir’s restarted dose cohorts, patient adherence, HbF response and ongoing monitoring for hematological malignancies or other safety signals.
- Reassess cash burn, investment liquidity and the stated runway into 2026 against trial costs, financing activity and any new ATM issuance.
- Check the status and potential financial or disclosure consequences of the securities class action and the company’s new ATM program.
- Monitor MyoKardia and CAMP4 program progress, contingent milestone and royalty obligations, and the impact of the strategic wind-down on pipeline breadth.